Cargando…

Correction to: Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study

Detalles Bibliográficos
Autores principales:	Hattori, Masaya, Ishiguro, Hiroshi, Masuda, Norikazu, Yoshimura, Akiyo, Ohtani, Shoichiro, Yasojima, Hiroyuki, Morita, Satoshi, Ohno, Shinji, Iwata, Hiroji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2017
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5741781/ https://www.ncbi.nlm.nih.gov/pubmed/29159517 http://dx.doi.org/10.1007/s12282-017-0815-7

Ejemplares similares

Phase I dose-finding study of eribulin and capecitabine for metastatic breast cancer: JBCRG-18 cape study
por: Hattori, Masaya, et al.
Publicado: (2017)

A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17)
por: Fukada, Ippei, et al.
Publicado: (2021)

Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
por: Aogi, Kenjiro, et al.
Publicado: (2021)

Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
por: Aogi, Kenjiro, et al.
Publicado: (2021)

Correction to: Clinical usefulness of eribulin as first- or second-line chemotherapy for recurrent HER2-negative breast cancer: a randomized phase II study (JBCRG-19)
por: Aogi, Kenjiro, et al.
Publicado: (2022)

Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01
por: Yamashiro, Hiroyasu, et al.
Publicado: (2020)

Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study
por: Ueno, Takayuki, et al.
Publicado: (2019)

Comparison of different definitions of pathologic complete response in operable breast cancer: a pooled analysis of three prospective neoadjuvant studies of JBCRG
por: Kuroi, Katsumasa, et al.
Publicado: (2014)

Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2–positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study)
por: Yamashita, Toshinari, et al.
Publicado: (2020)

Eribulin-based neoadjuvant chemotherapy for triple-negative breast cancer patients stratified by homologous recombination deficiency status: a multicenter randomized phase II clinical trial
por: Masuda, Norikazu, et al.
Publicado: (2021)

Factors associated with prolonged overall survival in patients with postmenopausal estrogen receptor-positive advanced breast cancer using real-world data: a follow-up analysis of the JBCRG-C06 Safari study
por: Kawaguchi, Hidetoshi, et al.
Publicado: (2019)

Fulvestrant with or without anti‐HER2 therapy in patients in a postmenopausal hormonal state and with ER‐positive HER2‐positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG‐C06)
por: Masuyama, Misato, et al.
Publicado: (2023)

Meta-analysis of nanoparticle albumin-bound paclitaxel used as neoadjuvant chemotherapy for operable breast cancer based on individual patient data (JBCRG-S01 study)
por: Futamura, Manabu, et al.
Publicado: (2021)

Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR
por: Ueno, Takayuki, et al.
Publicado: (2022)

An overview of the Japan Breast Cancer Research Group (JBCRG) activities
por: Ohno, Shinji, et al.
Publicado: (2013)

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
por: Yamashita, Toshinari, et al.
Publicado: (2020)

Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
por: Yamashita, Toshinari, et al.
Publicado: (2020)

Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study
por: Yamamoto, Yutaka, et al.
Publicado: (2020)

Bi-weekly eribulin therapy for metastatic breast cancer: a multicenter phase II prospective study (JUST-STUDY)
por: Ohtani, Shoichiro, et al.
Publicado: (2018)

Analysis of subsequent therapy in Japanese patients with hormone receptor‒positive/human epidermal growth factor receptor 2‒negative advanced breast cancer who received palbociclib plus endocrine therapy in PALOMA-2 and -3
por: Masuda, Norikazu, et al.
Publicado: (2020)

A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S−1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG‐M01 study)
por: Ishiguro, Hiroshi, et al.
Publicado: (2017)

Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR
por: Ueno, Takayuki, et al.
Publicado: (2019)

Eribulin improved the overall survival from the initiation of first-line chemotherapy for HER2-negative advanced breast cancer: a multicenter retrospective study
por: Nakamoto, Shogo, et al.
Publicado: (2022)

Long-Term Outcomes of a Randomized Study of Neoadjuvant Induction Dual HER2 Blockade with Trastuzumab and Lapatinib Followed by Weekly Paclitaxel Plus Dual HER2 Blockade for HER2-Positive Primary Breast Cancer (Neo-Lath Study)
por: Tokunaga, Eriko, et al.
Publicado: (2021)

Capecitabine for primary breast cancer
por: Toi, Masakazu, et al.
Publicado: (2017)

A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer
por: Masuda, Norikazu, et al.
Publicado: (2020)

Pembrolizumab plus chemotherapy in Japanese patients with triple‐negative breast cancer: Results from KEYNOTE‐355
por: Hattori, Masaya, et al.
Publicado: (2023)

Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy
por: Shimomura, Akihiko, et al.
Publicado: (2019)

Efficacy, safety, pharmacokinetics and biomarker findings in patients with HER2-positive advanced or metastatic breast cancer treated with lapatinib in combination with capecitabine: results from 51 Japanese patients treated in a clinical study
por: Iwata, Hiroji, et al.
Publicado: (2013)

Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management
por: Yoshimura, Akiyo, et al.
Publicado: (2022)

Bone Scan Index predicts skeletal-related events in patients with metastatic breast cancer
por: Idota, Ai, et al.
Publicado: (2016)

Comparison of an AC‐taxane versus AC‐free regimen and paclitaxel versus docetaxel in patients with lymph node‐positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study
por: Watanabe, Toru, et al.
Publicado: (2017)

Palbociclib‐letrozole as first‐line treatment for advanced breast cancer: Updated results from a Japanese phase 2 study
por: Takahashi, Masato, et al.
Publicado: (2020)

Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2018)

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2019)

Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan
por: Lin, Yu-Ju, et al.
Publicado: (2021)

Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)
por: Nakayama, Takahiro, et al.
Publicado: (2021)

A multicenter phase II trial of neoadjuvant letrozole plus low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer (JBCRG‐07): therapeutic efficacy and clinical implications of circulating endothelial cells
por: Ueno, Takayuki, et al.
Publicado: (2018)

Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer
por: Iwasa, Tsutomu, et al.
Publicado: (2019)

A phase 1b/2, open-label, dose-escalation, and dose-confirmation study of eribulin mesilate in combination with capecitabine
por: Twelves, Chris, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2kudueqkaupvio1k65qcjhb5an